Key Developments: Abbott Laboratories (ABT)

ABT on New York Consolidated

47.22USD
2 Mar 2015
Change (% chg)

$-0.15 (-0.32%)
Prev Close
$47.37
Open
$47.34
Day's High
$47.63
Day's Low
$47.13
Volume
7,016,259
Avg. Vol
5,575,639
52-wk High
$47.88
52-wk Low
$36.65

Search Stocks

Latest Key Developments (Source: Significant Developments)

Mylan completes acquisition of Abbott Laboratories's Non-U.S. developed markets specialty and branded generics business
Friday, 27 Feb 2015 12:30pm EST 

Mylan N.V. and Mylan Inc:Complete acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business.Under the previously announced terms of the transaction agreement, Abbott received 110 million shares of Mylan N.V., resulting in former Mylan Inc. shareholders now owning about 78pct of Mylan N.V. and Abbott now owning about 22pct of Mylan N.V. Mylan Inc.  Full Article

Abbott Laboratories declares quarterly dividend
Friday, 20 Feb 2015 10:36am EST 

Abbott Laboratories:Declares quarterly common dividend of 24 cents per share.Says cash dividend is payable May 15, to shareholders of record at the close of business on April 15.  Full Article

Abbott Laboratories gives FY, Q1 2015 EPS guidance in line with analysts' estimates
Thursday, 29 Jan 2015 07:45am EST 

Abbott Laboratories:Issues FY 2015 guidance for earnings-per-share (EPS) from continuing operations, excluding specified items, of $2.10 to $2.20.Including net specified items, projected earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) would be $1.33 to $1.43 for FY 2015.Issues Q1 2015 guidance for earnings-per-share guidance from continuing operations, excluding specified items, of $0.41 to $0.43.Including specified items, projected earnings-per-share from continuing operations under GAAP would be $0.18 to $0.20 for Q1 2015.FY 2015 EPS of $2.14 and Q1 2015 EPS of $0.41 - Thomson Reuters I/B/E/S.  Full Article

Abbott Laboratories completes acquisition of Topera, Inc.
Monday, 22 Dec 2014 04:30pm EST 

Abbott Laboratories:Completes its acquisition of Topera, Inc.Under the terms of the acquisition, Abbott acquired all outstanding equity of Topera for $250 mln upfront, plus potential future payments tied to performance milestones.  Full Article

Abbott Laboratories announces increase in quarterly dividend
Friday, 12 Dec 2014 11:18am EST 

Abbott Laboratories:Increases the company's quarterly common dividend to $0.24 per share from $0.22 per share.Payable Feb. 13, 2015, to shareholders of record on Jan. 15, 2015.  Full Article

Abbott Laboratories completes acquisition of Veropharm
Friday, 12 Dec 2014 12:03am EST 

Abbott Laboratories:Acquires control of Veropharm, a Russian pharmaceutical manufacturer.Through this acquisition, Abbott establishes a manufacturing footprint in Russia through Veropharm's production facilities, which include a new manufacturing facility currently under construction.Acquired control of Veropharm for 16.7 bln rubles (or about US$305 mln) through its purchase of Limited Liability Company Garden Hills, the holding company that currently owns about 98 pct of Veropharm.  Full Article

Abbott Laboratories to purchase Topera Inc
Wednesday, 29 Oct 2014 09:30am EDT 

Abbott Laboratories:Entered into an agreement to purchase Topera, Inc., a private, venture-backed medical device company focused on developing electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation.Completion of the Topera acquisition is subject to customary closing conditions, including antitrust clearance.Expected to close in the fourth quarter of this year.  Full Article

Abbott Laboratories narrows FY 2014 EPS outlook to a range above analysts' estimates; gives Q4 2014 EPS outlook in line with analysts' estimates
Wednesday, 22 Oct 2014 07:32am EDT 

Abbott Laboratories:Says it is raising the mid-point and narrowing its FY 2014 earnings-per-share guidance, excluding specified items, to $2.25 to $2.27 from $2.19 to $2.29, representing double-digit growth.Says including net specified items, projected earnings per share under GAAP would be $1.22 to $1.24 for FY 2014, including results from both continuing and discontinued operations.Expects Q4 2014 earnings-per-share guidance, excluding specified items, of $0.68 to $0.70, representing double-digit growth.Expects Q4 2014 including specified items, projected earnings-per-share under GAAP would be $0.32 to $0.34.FY 2014 EPS of $2.24 - Thomson Reuters I/B/E/S.Q4 2014 EPS of $0.70 - Thomson Reuters I/B/E/S.  Full Article

Abbott completes acquisition of CFR Pharmaceuticals
Friday, 26 Sep 2014 09:00am EDT 

Abbott Laboratories:Says has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding company's presence in fast-growing markets.Through purchase of controlling interest and tender offers described below, Abbott indirectly acquired more than 99 pct of CFR's ordinary shares for about $2.9 bln.  Full Article

Abbott Laboratories II study shows abbott's dissolving heart device comparable to Heart stent
Sunday, 14 Sep 2014 03:00pm EDT 

Abbott Laboratories:Announces positive one year clinical results from ABSORB II, the prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's metallic XIENCE family of DES.Says the trial, conducted primarily in Europe, included 501 people with coronary artery disease (CAD), the most common form of heart disease.  Full Article

UPDATE 1-Mylan still on the prowl for deals, perhaps one by end 2015

March 2 - U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week.

Search Stocks